Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer’s drug
By Ahmed Aboulenein WASHINGTON (Reuters) – The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzheimer’s drug Aduhelm, which was “rife with irregularities,” a congressional report showed on Thursday. The FDA’s interactions with Biogen were “atypical” and did not follow the agency’s …
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer’s drug Read More »









